Global Information
회사소개 | 문의

유전체학의 각종 제휴 계약 : 계약 조건 및 합의 내용

Global Genomics Partnering 2010-2018

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2018년 10월 상품 코드 712893
페이지 정보 영문 500+ Pages
가격
US $ 2,995 ₩ 3,409,000 PDF by E-mail (Single User License)
US $ 4,495 ₩ 5,117,000 PDF by E-mail (Multi User License - 2 to 5 Users)
US $ 8,995 ₩ 10,239,000 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 14,995 ₩ 17,070,000 PDF by E-mail (Global License)


유전체학의 각종 제휴 계약 : 계약 조건 및 합의 내용 Global Genomics Partnering 2010-2018
발행일 : 2018년 10월 페이지 정보 : 영문 500+ Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

유전체학(Genomics)에 관련된 최근의 각종 제휴 계약에 대해 조사했으며, 최근의 경향과 동향, 제휴 계약을 활발하게 맺고 있는 기업, 주요 대규모 계약, 각종 제휴 계약의 거래액·계약 유형·기술 구분·합의 내용·목적·조건 등의 각종 데이터를 정리하여 전해드립니다.

주요 요약

제1장 서론

제2장 유전체학의 각종 계약 동향

  • 서론
  • 과거 몇 년간의 제휴 동향
  • 제휴 계약을 활발하게 맺고 있는 기업
  • 제휴 계약 동향 : 계약 유형별
  • 제휴 계약 동향 : 치료 영역별
  • 제휴 계약 동향 : 산업 부문별
  • 계약 내용
    • 거래총액
    • 선불금
    • 마일스톤
    • 로열티율

제3장 주요 계약

  • 서론
  • 대형 계약 : 계약액별

제4장 제휴 계약을 활발하게 맺고 있는 기업

  • 서론
  • 제휴 계약을 활발하게 맺고 있는 기업
  • 제휴 계약을 활발하게 맺고 있는 기업 : 기업 개요

제5장 유전체학 계약 디렉토리

제6장 유전체학 계약 동향 : 기술 유형별

  • 유전체학

제7장 제휴 자료 센터

  • 온라인 제휴
  • 제휴 이벤트

부록

LSH 18.10.12

The “Global Genomics Partnering Terms and Agreements 2010 to 2018 report” provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in Genomics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Genomics partnering contract documents
  • Top Genomics deals by value

The “Global Genomics Partnering Terms and Agreements report” provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Genomics agreements announced in the healthcare sectors, covering:

  • Genomics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual Genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Genomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Genomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active Genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Genomics dealmaking with a brief summary followed by a comprehensive listing of Genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Genomics partnering company A-Z, deal type definitions and Genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genomics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genomics technologies and products.

Report scope

“Global Genomics Partnering Terms and Agreements 2010 to 2018” is intended to provide the reader with an in-depth understanding and access to Genomics trends and structure of deals entered into by leading companies worldwide.

“Global Genomics Partnering Terms and Agreements 2010 to 2018” includes:

  • Trends in Genomics dealmaking in the biopharma industry since 2010
  • Analysis of Genomics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Genomics deals
  • Access to over 200 Genomics deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active Genomics dealmakers since 2010
  • The leading Genomics partnering resources

In “Global Genomics Partnering Terms and Agreements 2010 to 2018”, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

“Global Genomics Partnering Terms and Agreements 2010 to 2018” provides the reader with the following key benefits:

  • In-depth understanding of Genomics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Genomics agreements with numerous real life case studies
  • Comprehensive access to over 200 Genomics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Genomics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Genomics deals by value since 2010
  • Identify the most active Genomics dealmakers since 2010
  • Detailed access to actual Genomics contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Genomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genomics dealmaking

  • 2.1. Introduction
  • 2.2. Genomics partnering over the years
  • 2.3. Most active Genomics dealmakers
  • 2.4. Genomics partnering by deal type
  • 2.5. Genomics partnering by therapy area
  • 2.6. Genomics partnering by industry sector
  • 2.7. Deal terms for Genomics partnering
    • 2.7.1 Genomics partnering headline values
    • 2.7.2 Genomics deal upfront payments
    • 2.7.3 Genomics deal milestone payments
    • 2.7.4 Genomics royalty rates
  • 2.8. The anatomy of an Genomics deal
  • 2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
  • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
  • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Genomics deals

  • 3.1. Introduction
  • 3.2. Top Genomics deals by value

Chapter 4 - Most active Genomics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Genomics dealmakers
  • 4.3. Most active Genomics partnering company profiles

Chapter 5 - Genomics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Genomics contracts dealmaking directory

Chapter 6 - Genomics dealmaking by technology type

  • Genomics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Metronidazole
  • Penicillin
  • Quinolones
  • Tetracycline

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Genomics deals by company A-Z
  • Appendix 2 - Genomics deals by stage of development
  • Appendix 3 - Genomics deals by deal type
  • Appendix 4 - Genomics deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES:

  • Figure 1: Genomics partnering since 2010
  • Figure 2: Active Genomics dealmaking activity sincce 2010
  • Figure 3: Genomics partnering by deal type since 2010
  • Figure 4: Genomics partnering by disease type since 2010
  • Figure 5: Genomics partnering by industry sector since 2010
  • Figure 6: Genomics deals with a headline value
  • Figure 7: Genomics deals with an upfront value
  • Figure 8: Genomics deals with a milestone value
  • Figure 9: Genomics deals with a royalty rate value
  • Figure 10: Top Genomics deals by value since 2010
  • Figure 11: Most active Genomics dealmakers since 2010
  • Figure 12: Genomics partnering by technology type since 2010
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
Back to Top
전화 문의
이용안내
 
BCC Research